Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion
NCT01901692
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
RADIATION:
TACE+External beam RT
DRUG:
Sorafenib
Sponsor
Asan Medical Center